500 patients with rare immune defects to be tracked for years
NCT ID NCT06762002
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 39 times
Summary
This study follows 500 adults who either have a genetic defect or autoantibodies that weaken their type I interferon immune response. Researchers will collect blood samples and health data over 1 to 4 years to track infections, autoimmune diseases, and cancers. The goal is to better understand and manage these immune problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cic Bichat
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cic Creteil
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cic La Salpetriere
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cic Lille
RECRUITINGLille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cic Montpellier
RECRUITINGMontpellier, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cic Necker
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cic St Louis
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cic Tours
RECRUITINGTours, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
LYON HCL
RECRUITINGLyon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could improve how doctors monitor and manage patients with weakened type I interferon defenses, potentially reducing severe infections and autoimmune complications.
What could go wrong
This is an observational study, not a treatment trial. It will not directly test any new drug or therapy, so it cannot prove that any intervention works. Results may take years and might not lead to immediate changes in care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.